Centre d'Immunologie de Marseille Luminy CIML

What Centre d'Immunologie de Marseille Luminy CIML does

The Centre d'Immunologie de Marseille-Luminy (CIML) is a French public research institute founded in 1976 and jointly supervised by Aix-Marseille Université, CNRS, and Inserm. It is one of Europe's leading immunology research centers, organized around 27 research teams that study the immune system across innate lymphoid cells (including NK cells, ILC1, ILC2, ILC3), dendritic cells, B cell immunity, mucosal immunity, and T cell membrane dynamics. The institute's user base is the academic research community and, downstream, pharmaceutical/biotech partners such as Innate Pharma (founded 1999 from CIML discoveries by Alessandro Moretta and Eric Vivier), with whom it collaborates on translating fundamental immunology into cancer immunotherapies and antibody-based therapeutics.

CIML's underlying technology stack comprises advanced biophotonic platforms — single-molecule localization microscopy (SMLM), STED, fluorescence correlation spectroscopy, and novel super-resolution imaging approaches — supported by proprietary methods including the Quality Control Maps (QCM) framework for real-time quantitative control of SMLM data, developed in-house. The institute also participates in the EU FET-OPEN LINkS project investigating long-range electrodynamic interactions between proteins in living cells. These capabilities underpin research output published in top-tier journals including Cell, Nature Immunology, Science Immunology, Nature, and Cancer Discovery, and feed translational consortia such as RHU PIONeeR on PD-1/PD-L1-resistant non-small cell lung cancer.

The institute does not sell commercial products or services. Its revenue model consists of institutional funding from its three supervisory bodies, competitive grants from national agencies (ANR) and the European Union, and technology-transfer income via spin-off creation (notably Innate Pharma). CIML also operates an educational franchise, including a Master of Immunology program that received the amideX PLUS excellence label in 2024 under the France 2030 initiative. Communications with the scientific community occur through peer-reviewed publications, the institutional website, LinkedIn, and scientific conferences including the 50th anniversary symposium held in June 2025.

Name

Centre d'Immunologie de Marseille Luminy CIML

Legal name

Centre d'Immunologie de Marseille-Luminy

Website

https://ciml.univ-mrs.fr

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

1–10 employees

Short description

The Centre d'Immunologie de Marseille-Luminy (CIML) is a French public immunology research institute founded in 1976 and jointly supervised by Aix-Marseille Université, CNRS, and Inserm, organizing 27 research teams that study innate immunity, NK cells, and mucosal immunity for the academic community and biotech partners such as Innate Pharma.

Ownership category

akta.pro rank

Headquarters

HQ city

Marseille, 13

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Government Research Funding: CIML receives institutional funding from its supervisory bodies: Aix-Marseille Université, CNRS (French National Center for Scientific Research), and Inserm (French National Institute of Health and Medical Research). Additional funding comes from European research grants (EU FET-OPEN, RHU PIONeeR) and national research programs.
2. Research Grants and Awards: Competitive research grants from national agencies (ANR), European Union frameworks, and private foundations supporting specific research projects and programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

CIML is a fundamental immunology research institute that conducts scientific research on the immune system, operating 27 research teams across topics including innate lymphoid cells, natural killer cells, dendritic cells, B cell immunity, mucosal immunity, and membrane dynamics. The institute also delivers graduate-level training through a Master of Immunology program and provides access to advanced technology platforms such as super-resolution microscopy.

Product overview

CIML (Centre d'Immunologie de Marseille-Luminy) is a fundamental immunology research institute founded in 1976, jointly supervised by Aix-Marseille Université, CNRS, and Inserm. The institute does not offer commercial products or services; rather, it operates as a scientific research center conducting fundamental research on the immune system. Research teams study Natural Killer cells, innate lymphoid cells, dendritic cells, B cell immunity, mucosal immunity, and T cell membrane dynamics and signaling. The institute provides access to technology platforms and publishes scientific findings, operating under academic and public research frameworks rather than commercial product offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Master of Immunology Degree Program Graduate-level educational program training the next generation of immunology researchers, delivered by CIML under Aix-Marseille Université and recognized with the amideX PLUS excellence label.
• Immunology Research Collaboration Services Collaborative scientific research services for academic institutions and pharmaceutical/biotech companies, including joint projects, technology transfer, and licensing of research innovations such as NK cell-based immunotherapies (exemplified by Innate Pharma).

Quantifiable outcome

• CIML researchers publish extensively in high-impact journals including Cell, Nature, Science Immunology, and Nature Immunology
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• EU FET-OPEN (LINkS Project)coreStrategic or Co-development Partner · 1 January 2021European Union research funding program supporting the LINkS project on long-range electrodynamic interactions between proteins, investigating fundamental mechanisms of cellular organization.
• RHU PIONeeR ConsortiumcoreStrategic or Co-development Partner · 1 January 2019Hospital-University Research project on precision immuno-oncology for advanced non-small cell lung cancer patients with PD-1/PD-L1 inhibitor resistance, involving multiple clinical and research partners.
• Innate PharmaflagshipStrategic or Co-development Partner · 1 January 1999Immunotherapy company founded in 1999 based on discoveries by Alessandro Moretta and Eric Vivier from CIML. Develops NK cell-engager antibodies and immunotherapies. CIML maintains research collaborations translating discoveries into clinical applications.
• Aix-Marseille UniversitécoreStrategic or Co-development Partner · 1 January 1976Primary supervisory institution providing academic oversight, faculty appointments, and educational program support for CIML's research and training activities.
• CNRS (Centre National de la Recherche Scientifique)coreStrategic or Co-development Partner · 1 January 1976French national research agency serving as co-supervisor, providing institutional funding and research infrastructure support to CIML.
• Inserm (Institut National de la Santé et de la Recherche Médicale)coreStrategic or Co-development Partner · 1 January 1976French national medical research institute co-supervising CIML and providing funding and institutional support for biomedical research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• The Francis Crick Institute: Large UK biomedical research institute covering immunology, cancer biology, and infectious disease. A broader incumbent in fundamental immunology research with greater scale but similar academic, non-commercial operating model.
• German Cancer Research Center (DKFZ): Germany's largest biomedical research institute, conducting immunology and cancer immunotherapy research. Comparable in public funding model and translational cancer immunology mission, though much larger in scale.
• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization covering molecular biology including immunology-related research. Comparable in public funding model and fundamental research mission, though broader in scope.
• The Scripps Research Institute: Major US non-profit biomedical research organization with significant immunology and immunology-adjacent research programs. Comparable as a non-commercial research enterprise with translational pipelines.

Direct peers

• Institut Pasteur: France's flagship biomedical research institute, also under multi-institutional supervision and conducting immunology, infectious disease, and cell biology research. Directly comparable as a fundamental immunology research center with similar funding model and translational pipeline.
• Max Planck Institute for Immunobiology and Epigenetics: German research institute focused on immunobiology and epigenetics, with comparable team-based structure and fundamental immunology research mission. Comparable scope in NK cell, T cell, and innate immunity research.
• Babraham Institute: UK life sciences research institute focused on signaling, epigenetics, and immunology. Comparable in size and structure with similar emphasis on fundamental research, technology platforms, and graduate training.
• Whitehead Institute for Biomedical Research: US non-profit research institute affiliated with MIT, focused on fundamental biomedical research including immunology. Comparable in team-based structure, basic science mission, and graduate training programs.

Emerging players

• Innate Pharma: Immunotherapy company founded in 1999 from CIML discoveries, focused on NK cell-based cancer therapies. Closely linked translational spin-off rather than direct competitor, but exemplifies the commercial pathway from CIML science.

Regional players

• Centre for Genomic Regulation (CRG): Spanish biomedical research institute conducting immunology and systems biology research. Comparable European public research institute with similar team structure and fundamental science focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/centre-d'immunologie-de-marseille-luminy-ciml

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre d'Immunologie de Marseille Luminy CIML